Oxford, UK, April 17, 2008

PharmaVentures announced today the publication of the report ‘Competition Law and Intellectual Property Strategy in the Pharmaceuticals Sector’, written by Richard Eccles and Gerry Kamstra, partners in the leading international law firm, Bird & Bird, in London. Fintan Walton, PhD, PharmaVentures’ Chief Executive Officer, says, ‘In our work facilitating strategic transactions within the pharmaceutical and biotech industry worldwide, awareness of the latest competition legislation is crucial as it affects technology licensing, marketing and distribution agreements. In publishing this Report, we are delighted to have collaborated with Bird & Bird who have contributed their leading-edge expertise ’.

Lead Author of the Report, Richard Eccles says, ‘We give advice to our clients every day on IP, competition law and regulatory matters, but have been unable to point to a single recent publication which provided business development and licensing executives in the Pharmaceutical and biotech industry with a succinct but comprehensive overview. In writing this Report, we hope to serve this need, and to help keep the industry informed in an area central to their strategic decision-making’.

The Report addresses topics such as how legislation and case law affects patent enforcement, the conduct of dominant suppliers under the EC competition rules, the use of IP rights against parallel imports, pricing issues, R&D agreements, technology licensing agreements, as well as private enforcement of competition rules. Leading cases involving, for example, GlaxoSmithKline, Boehringer Ingelheim, Bayer, AstraZeneca, Napp Pharmaceuticals and Genzyme are covered to illustrate the key points made.

Published under PharmaVentures’ imprint PharmaDeals®, the new Report is a co-publication between PharmaVentures Ltd and Bird & Bird.

About PharmaVentures

PharmaVentures assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company’s core business is the provision of tailored transaction advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals® range of publishing products that include databases, analysis tools, and reports. PharmaVentures is based in Oxford, UK, and employs over 35 people. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporate pharmaceutical companies.

Competition Law and Intellectual Property Strategy in the Pharmaceuticals sector

Report by Bird & Bird for PharmaVentures

Richard Eccles and Gerry Kamstra, Bird & Bird

ISBN 978-0-9558821-0-4 

Order Form

About Bird & Bird

Bird & Bird is an international commercial law firm specialising in technology-focused sectors including life sciences and combining leading-edge legal expertise with an in-depth understandoing of these industries. Many of its lawyers are ranked as leading individuals in their specialist fields in top legal directories, including Richard Eccles for EU and competition law and Gerry Kamstra for patent, regulatory and commercial law.

– ends –

Oxford, UK, April 4, 2008

PharmaVentures announced today that it acted as advisor to the Dow Chemical Company (NYSE:DOW) for the sale of Dowpharma Small Molecules business to Dr. Reddy’s Laboratories (NYSE:RDY). On April 1st 2008 Dr. Reddy’s Laboratories announced that it has entered into a definitive agreement with The Dow Chemical Company to acquire a portion of Dowpharma Small Molecules business associated with its United Kingdom sites in Mirfield and Cambridge.The financial terms and conditions of the transaction are not being disclosed at this point in time. The transaction is scheduled to close on April 30, 2008 pending regulatory approval. The acquisition will include the relevant business, customer contracts, associated products, process technology, intellectual property, trademarks as well as the transfer of the facilities at Mirfield and Cambridge in the United Kingdom. The two sites and the business employ around 80 people. Dr. Reddy’s will also have a non-exclusive license to Dow’s Pfēnex Expression Technology™ for biocatalysis development.

Dr Fintan Walton, CEO, PharmaVentures said, “We were delighted to act as advisors and facilitators to The Dow Chemical Company in the divestment of its Small Molecules Business and we were pleased to work with such a professional team”.

About PharmaVentures

PharmaVentures (http://www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company’s core business is the provision of tailored transaction advisory services to the Life Science industry. PharmaVentures is based in Oxford, UK, and employs over 35 people. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporations.

About Dr. Reddy’s

Dr. Reddy’s Laboratories was established in 1984 in Hyderabad, India, and is a global pharmaceutical company with proven research capabilities. Dr. Reddy’s conducts research in the areas of diabetes, obesity, cardiovascular diseases, anti-infectives and inflammation. The Indian based company produces finished dosage forms, active pharmaceutical ingredients and biotechnology products which are marketed globally, with focus on India, US, Europe and Russia.www.drreddys.com

About The Dow Chemical Company

With annual sales of $54 billion and 46,000 employees worldwide, Dow is a diversified chemical company that combines the power of science and technology with the “Human Element” to constantly improve what is essential to human progress. The Company delivers a broad range of products and services to customers in around 160 countries, connecting chemistry and innovation with the principles of sustainability to help provide everything from fresh water, food and pharmaceuticals to paints, packaging and personal care products. More information about Dow can be found at www.dow.com

– ends –

Oxford Science Park, Oxford, UK, 5 March, 2008

PharmaVentures announced today the appointment of Anne Vindenes Allen MSc as Chief Operating Officer of PharmaDeals, the new publishing division of PharmaVentures Ltd. Fintan Walton, PhD, PharmaVentures’ Chief Executive Officer says, “We have a large and loyal following for the PharmaDeals database within the pharmaceutical and biotechnology business sector, and have plans to roll out some truly exciting developments in the coming months. We are delighted Anne will join us to steer these developments. Her experience of managing complex web technology implementations combined with her publishing expertise will be invaluable in helping us position our products to better serve our discerning customers.”

Anne says, “The PharmaDeals database is internationally renowned for the quality of its content, and not least its depth of coverage. We are extremely fortunate in having world leading experts at hand here at PharmaVentures to advise us in taking this premier resource to the next level”. In addition to directing PharmaDeals, Anne will take forward PharmaDeals Reports publications, a portfolio of books and reports focused on deals and alliances. Ms Allen will also contribute to the technical development of PharmaTelevision, the innovating web television channel.

A life scientist by training, Anne gained her publishing and management experience over nine years at Elsevier Science, the world’s largest STM publisher, latterly as Publisher for a highly successful environmental sciences programme. Her knowledge and interest in new publishing technologies came in good stead as Editorial Director at Infotrieve Inc, where she contributed to the conceptual development of the Life Science Resource Centre database product. As Managing Director of TheScientificWorld Ltd, the scholarly publisher for biomedical sciences, Anne was responsible for designing and implementing their innovating scholarly journal platform. “It’s an exciting new challenge; this is a smart company with smart ideas serving a high level audience. We have to deliver real quality of product and service – and my aim would be to ensure that PharmaDeals continues to be the preferred choice for all pharmaceutical and biotechnology companies, and also interested stakeholders in academia worldwide.”

– ends –

With over 24,000 deals and alliances completed in the Life Science industry over the past 10 years, current and readily available statistics and insight is an essential part of business development. PharmaVentures, a leading provider of specialist consultancy and intelligence services, has launched a bespoke on-demand, 48 hour turn-around analysis service, PharmaDeals® Research.

Aimed at busy executives needing access to high quality and timely deal analysis information, this new service, enables licensing , business development and senior executives to quickly obtain the answers to their specific deal and competitor-related questions, whenever they need them, to support negotiations, valuations and transactions.

The PharmaVentures team of business analysts working on PharmaDeals® Research combine direct, in-depth pharmaceutical industry experience with advanced scientific and business qualifications. The analysts are able to research and produce a range of intelligence data in the following areas; benchmark reporting, deal area analysis, contract analysis and deal insight, equipping executives with exactly the intelligence they need to negotiate and structure deals successfully.

Fintan Walton, CEO of PharmaVentures said; “PharmaVentures serves the global pharmaceutical industry and has advised over 1000 companies in 38 countries in driving their development. We have a comprehensive intelligence bank containing constantly updated worldwide industry information. PharmaDeals® Research builds on this information and the service was developed after we identified that there was demand from companies wanting quick access to tailored analysis. By having this intelligence at their fingertips executives are better empowered to make sound decisions, equipped with the latest views of the industry.”

Executives are able to subscribe to PharmaDeals® Research using a flexible credit method system. Each request will use a certain number of credits, and credits not used in the year can be carried over to the next year. Credit can also be used against PharmaVentures consultancy services.

For more information on PharmaDeals® Research please contact 01865 784 177 or emailenquiries@pharmaventures.com

– ends –

The revolutionary global media channel for the pharmaceutical and biotech industry, PharmaTelevision, is celebrating its one year anniversary. Launched on May 18th 2006 and with viewing figures now averaging 8,000 per programme, the site is fast becoming one of the most popular channels for insight and intelligence across the industry.

The brainchild of PharmaVentures, a leading strategic advisory consultancy, based in Oxford, UK, the channel hosts weekly interviews with some of the industry’s key figures. Over the past year the CEO of PharmaVentures, Fintan Walton and his team have interviewed over 70 people including Rob Hockney, AstraZeneca, Eric de la Fortelle, Roche and Rob Wills, Johnson & Johnson.

Filmed at a variety of locations across the globe, including San Francisco, New York, Sydney and London’s Millbank Studios, the PharmaVentures Business Review programme examines trends and issues in the deals making arena. Each month, the programme covers a new therapeutic area or business related issue in the Month-in-Review, Business Report and Face-to-Face interview. These segments of the programme provide news on the key deals, discuss deal making trends, and give essential insight from industry experts.

Fintan Walton aims to expand and develop PharmaTelevision further in 2007, with the addition of new programmes and even more content. He comments “The industry is constantly changing and accessible mediums like these are essential to ensure busy people are up to speed and ahead of the game where possible. The site offers viewers the opportunity to gain valuable advice, position themselves as thought leaders and of course to showcase their business.

“PharmaTelevision is an exciting concept and the prospects for it are immense. We’d like to thank everyone who has supported us in its inaugural year and are calling for potential interviewees to contact us.”

A leading results driven organisation, PharmaVentures (www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. It provides tailored consulting services and adds value to deals through the PharmaDeals range of intelligence products which includes analysis tools, reports and workshops.

– ends –